Tarcisio: Instituto Butantan gained a new business arm, which is the pharmaceuticals arm.
Tarcisio: So it's working with immunobiologicals and will start working with pharmaceuticals as well.
Since Butantan is working with monoclonal antibodies and is developing monoclonal antibody manufacturing, it will be able to enter the production of high-cost drugs.
Tarcisio: Drugs for rheumatic disease, drugs for cancer.
Tarcisio: It used to manufacture 400 million medicines.